Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a phosphate binder curb kidney stone risk?

NCT ID NCT03346369

Disease control Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether lanthanum carbonate, a drug typically used to bind phosphate, can also reduce oxalate levels in urine. People with secondary hyperoxaluria and a history of kidney stones take the drug with meals for 28 days, with the dose increasing after two weeks. The goal is to see if this approach safely lowers urinary oxalate, a key driver of stone formation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lanthanum carbonate (Fosrenol), a phosphate binder taken with meals
What this could lead to
If effective, this could offer a new way to lower urine oxalate and potentially reduce kidney stone formation in people with secondary hyperoxaluria.
What could go wrong
This is a short-term, open-label trial with a small number of participants, so results may not be conclusive or generalizable. Possible side effects include gastrointestinal issues and phosphate depletion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

54 people

The number who actually took part.

Started

Aug 2017

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * able to give written informed consenct * hyperoxaluria (defined as urinary oxalate \> 45 mg/24 hours), demonstrated on 24-hour urine collection within 18 months prior to baseline visit * history of nephrolithiasis eGFR \> 60 mL/min/1.73m² (CKD-EPI formula) Exclusion Criteria: * primary hyperoxaluria, diagnosed by genetic testing * known allergy to Lanthanum Carbonate * hypophosphatemia (defined as serum phosphorus \< 0.81 mmol/L) * severe known liver insufficiency of biliary obstruction * rectocolitis ulcerohaemorraghica, Crohn's disease, bowel obstruction, stomach/duodenal ulceration * glucose/galactose malabsorption * severe diarrhea or other gastrointestinal disorder, which might interfere with the ability to absorb oral medication * pregnancy or breast-feeding * female participant of childbearing potential unwilling to take efficient contraceptive measures for the duration of the study * female participant without negative serum or urine pregnancy test * psychological illness or condition, interfering with the patient's compliance or ability to understand the requirements of the study * currently participating in another clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nephrolithiasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperoxaluria nephrolithiasis urolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nephrolithiasis Secondary hyperoxaluria

Contacts and locations

Locations

  • University Hospital Brussels

    Brussels, 1090, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.